{"id":170,"date":"2019-10-17T22:19:06","date_gmt":"2019-10-17T22:19:06","guid":{"rendered":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/4-11-beta-1-agonist\/"},"modified":"2025-01-16T22:25:50","modified_gmt":"2025-01-16T22:25:50","slug":"4-11-beta-1-agonist","status":"publish","type":"chapter","link":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/4-11-beta-1-agonist\/","title":{"raw":"4.11 Beta-1 Agonists","rendered":"4.11 Beta-1 Agonists"},"content":{"raw":"Dobutamine is a Beta-1 agonist.\n\n<strong>Mechanism of Action:<\/strong> Dobutamine stimulates Beta-1 receptors to increase heart rate, force of contraction, and conduction velocity.\n\n<strong>Indications:<\/strong> Dobutamine is used to treat cardiogenic shock and severe heart failure to increase contractility and cardiac output.\n\n<strong>Nursing Considerations:<\/strong> In IV administration, dilute concentration before administering. Continuously monitor electrocardiogram (ECG), blood pressure, cardiac output, and urine output during therapy.\n\n<strong>Side Effects\/Adverse Effects: <\/strong>Adverse effects of Beta-1 agonists include marked increase in heart rate and blood pressure. Individuals should promptly report difficulty breathing, angina, palpitations, or dizziness.\n\n<strong>Health Teaching &amp; Health Promotion: <\/strong>The client should be instructed to inform the nurse immediately if they notice chest pain, shortness of breath, or numbness or tingling in the extremities.<sup>[footnote]uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]<\/sup>\n\nNow let's take a closer look at the dobutamine medication grid in Table 4.11.<sup>[footnote]This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" target=\"_blank\" rel=\"noopener noreferrer\">DailyMed<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the <a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" target=\"_blank\" rel=\"noopener noreferrer\">Public Domain<\/a>.[\/footnote]<\/sup>\n\nTable 4.11 Dobutamine Medication Grid\n<table class=\"grid\" border=\"0\">\n<tbody>\n<tr>\n<th class=\"shaded\" style=\"width: 132.063px\" scope=\"col\">\n<h5><strong>Class\/Subclass<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" style=\"width: 165.063px\" scope=\"col\">\n<h5><strong>Prototype\/Generic<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" style=\"width: 380.063px\" scope=\"col\">\n<h5><strong>Nursing Considerations<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" style=\"width: 341.063px\" scope=\"col\">\n<h5><strong>Therapeutic Effects<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" style=\"width: 282.063px\" scope=\"col\">\n<h5><strong>Side\/Adverse Effects<\/strong><\/h5>\n<\/th>\n<\/tr>\n<tr>\n<th style=\"width: 132.063px\" scope=\"row\">Beta-1 Agonist<\/th>\n<td style=\"width: 165.063px\"><a class=\"arrow\" href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead&amp;audience=consumer\" target=\"_blank\" rel=\"noopener noreferrer\">dobutamine<\/a><\/td>\n<td style=\"width: 380.063px\">Continuously monitor ECG, blood pressure, cardiac output, and urine output during therapy<\/td>\n<td style=\"width: 341.063px\">Increases heart rate, force of heart contraction, cardiac output, and speed of conduction between SA to AV nodes<\/td>\n<td style=\"width: 282.063px\">Marked increase in heart rate and blood pressure\n\nReport all adverse reactions promptly, especially labored breathing, angina, palpitations, and dizziness<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n&nbsp;","rendered":"<p>Dobutamine is a Beta-1 agonist.<\/p>\n<p><strong>Mechanism of Action:<\/strong> Dobutamine stimulates Beta-1 receptors to increase heart rate, force of contraction, and conduction velocity.<\/p>\n<p><strong>Indications:<\/strong> Dobutamine is used to treat cardiogenic shock and severe heart failure to increase contractility and cardiac output.<\/p>\n<p><strong>Nursing Considerations:<\/strong> In IV administration, dilute concentration before administering. Continuously monitor electrocardiogram (ECG), blood pressure, cardiac output, and urine output during therapy.<\/p>\n<p><strong>Side Effects\/Adverse Effects: <\/strong>Adverse effects of Beta-1 agonists include marked increase in heart rate and blood pressure. Individuals should promptly report difficulty breathing, angina, palpitations, or dizziness.<\/p>\n<p><strong>Health Teaching &amp; Health Promotion: <\/strong>The client should be instructed to inform the nurse immediately if they notice chest pain, shortness of breath, or numbness or tingling in the extremities.<sup><a class=\"footnote\" title=\"uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral\" id=\"return-footnote-170-1\" href=\"#footnote-170-1\" aria-label=\"Footnote 1\"><sup class=\"footnote\">[1]<\/sup><\/a><\/sup><\/p>\n<p>Now let&#8217;s take a closer look at the dobutamine medication grid in Table 4.11.<sup><a class=\"footnote\" title=\"This work is a derivative of DailyMed by U.S. National Library of Medicine in the Public Domain.\" id=\"return-footnote-170-2\" href=\"#footnote-170-2\" aria-label=\"Footnote 2\"><sup class=\"footnote\">[2]<\/sup><\/a><\/sup><\/p>\n<p>Table 4.11 Dobutamine Medication Grid<\/p>\n<table class=\"grid\">\n<tbody>\n<tr>\n<th class=\"shaded\" style=\"width: 132.063px\" scope=\"col\">\n<h5><strong>Class\/Subclass<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" style=\"width: 165.063px\" scope=\"col\">\n<h5><strong>Prototype\/Generic<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" style=\"width: 380.063px\" scope=\"col\">\n<h5><strong>Nursing Considerations<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" style=\"width: 341.063px\" scope=\"col\">\n<h5><strong>Therapeutic Effects<\/strong><\/h5>\n<\/th>\n<th class=\"shaded\" style=\"width: 282.063px\" scope=\"col\">\n<h5><strong>Side\/Adverse Effects<\/strong><\/h5>\n<\/th>\n<\/tr>\n<tr>\n<th style=\"width: 132.063px\" scope=\"row\">Beta-1 Agonist<\/th>\n<td style=\"width: 165.063px\"><a class=\"arrow\" href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6b17b98b-e06d-42ed-925f-69aa2699dead&amp;audience=consumer\" target=\"_blank\" rel=\"noopener noreferrer\">dobutamine<\/a><\/td>\n<td style=\"width: 380.063px\">Continuously monitor ECG, blood pressure, cardiac output, and urine output during therapy<\/td>\n<td style=\"width: 341.063px\">Increases heart rate, force of heart contraction, cardiac output, and speed of conduction between SA to AV nodes<\/td>\n<td style=\"width: 282.063px\">Marked increase in heart rate and blood pressure<\/p>\n<p>Report all adverse reactions promptly, especially labored breathing, angina, palpitations, and dizziness<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<hr class=\"before-footnotes clear\" \/><div class=\"footnotes\"><ol><li id=\"footnote-170-1\">uCentral from Unbound Medicine. <a href=\"https:\/\/www.unboundmedicine.com\/ucentral\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/www.unboundmedicine.com\/ucentral<\/a> <a href=\"#return-footnote-170-1\" class=\"return-footnote\" aria-label=\"Return to footnote 1\">&crarr;<\/a><\/li><li id=\"footnote-170-2\">This work is a derivative of <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/\" target=\"_blank\" rel=\"noopener noreferrer\">DailyMed<\/a> by <a href=\"https:\/\/www.nlm.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">U.S. National Library of Medicine<\/a> in the <a href=\"https:\/\/creativecommons.org\/share-your-work\/public-domain\/\" target=\"_blank\" rel=\"noopener noreferrer\">Public Domain<\/a>. <a href=\"#return-footnote-170-2\" class=\"return-footnote\" aria-label=\"Return to footnote 2\">&crarr;<\/a><\/li><\/ol><\/div>","protected":false},"author":83,"menu_order":11,"template":"","meta":{"pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":[],"pb_section_license":""},"chapter-type":[48],"contributor":[],"license":[],"class_list":["post-170","chapter","type-chapter","status-publish","hentry","chapter-type-numberless"],"part":140,"_links":{"self":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/users\/83"}],"version-history":[{"count":1,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/170\/revisions"}],"predecessor-version":[{"id":171,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/170\/revisions\/171"}],"part":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/parts\/140"}],"metadata":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/170\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/media?parent=170"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapter-type?post=170"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/contributor?post=170"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/license?post=170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}